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INTRODUCTION
Various modalities such as radical prostatectomy (RP), 
radiation therapy (RT), and systemic therapy have been 
used to treat prostate cancer. Conventionally, RP and RT 
have been offered with the aim of curing localized prostate 
cancer [1]. Such definitive local therapies are usually not 
considered in cases of advanced or metastatic disease, for 
which systemic therapy such as androgen deprivation 
therapy (ADT) has been used for a palliative aim, even if 
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there is only single lymph node (LN)-positive disease [2]. In 
advanced or metastatic prostate cancer, ADT is used to delay 
disease progression and relieve cancer-related or metastasis-
related symptoms [3,4].
Since the use of  prostate-specific antigen (PSA) mea-
surement in clinical practice, the proportion of advanced 
prostate cancer at the time of initial diagnosis has decreased. 
During the early PSA era, Smith et al. [5] reported that the 
proportion of men with pathologically advanced cancer was 
reduced from 33% to 27%. Some years later, Ryan et al. [6] 
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reported that the rate of metastatic prostate cancer at the 
time of first diagnosis had decreased from 4.2% since 1998 to 
1.6%. However, a significant number of patients undergoing 
local therapy will experience biochemical recurrence. 
Recently, Mullins et al. [7] observed that 10-, 15-, 20-, and 25-
year rates of biochemical recurrence were 18%, 22%, 26%, and 
32% in a study that reported 30-year oncological outcomes of 
4,478 open RPs performed by a single surgeon between 1982 
and 2011. 
Among patients with metastatic or recurrent prostate 
cancer, some patients may have oligometastatic status. 
Oligometastasis is a minimal metastatic status that is 
considered an intermediate state between localized di-
sease and widespread metastasis [8]. The importance of 
oligometastasis is that local therapy for the primary tumor 
or metastasis-directed therapy could be performed with a 
curative aim in selected patients with limited metastasis [9]. 
Actually, many studies have shown that local therapy for 
the primary tumor is associated with improved survival in 
other malignancies such as renal cell cancer, colon cancer, 
and glioblastoma [10-12]. 
Some studies have inferred that oligometastatic prostate 
cancer is related to favorable oncologic outcomes. In these 
studies, a fewer number of metastatic lesions was associated 
with improved survival in patients with metastatic disease. 
In addition, metastatic lesions were also important predictors 
for survival [13-15]. However, few studies of  the benefit 
of  metastasis-directed or local therapy in patients with 
oligometastatic prostate cancer are available. Here we review 
not only studies about the management of oligometastatic 
prostate cancer but also studies about “common” metastatic 
prostate cancer. In addition, we assess the role of metastasis-
directed or local therapy for oligometastatic prostate cancer. 
TREATMENT OF OLIGOMETASTATIC 
PROSTATE CANCER
1. Definition of oligometastasis in prostate cancer
It is important to define oligometastatic prostate cancer 
when carrying out studies. Unfortunately, however, there 
has been no consensus on the definition of oligometastasis 
in prostate cancer. But some studies are available that can 
help to determine the number of  metastatic lesions for 
oligometastasis. For example, Soloway et al. [16] evaluated 
the relation of extent of metastatic lesions and survival by 
using a semiquantitative grading system. They found that 
the 2-year survival rate in patients who had fewer than six 
bone metastases on a bone scan was 96%. Singh et al. [17] 
reported that patients with 5 or fewer metastatic lesions 
had significantly better survival rates than did patients 
with more than 5 lesions. Thus, referring to these studies, 
it might seem reasonable to define oligometastasis as 5 or 
fewer metastatic lesions. However, most studies related to 
oligometastasis have used their own definition (Table 1).
2. Radiotherapy for oligometastatic prostate cancer
Most studies on the management of  oligometastatic 
prostate cancer have concerned the results of stereotactic RT 
on metastatic lesions. In the beginning, most studies focused 
on the safety and feasibility of  metastasis-directed RT. 
Jereczek-Fossa et al. [18] were the first to report the results 
of treatment with stereotactic RT for metastatic lesions. In 
that study, 14 patients were treated with CyberKnife image-
guided stereotactic RT for isolated LN recurrence. The 
authors observed that the local control rate was 100% at 18.6 
months and that there was no grade 3 toxicity. The same 
authors reported the results of RT on LN or bone metastasis 
some years after their first study [19]. They treated 34 
patients with 38 lesions and the local control rate was 88% 
at 16.9 months. The 30-month progression-free survival rate 
was reported as 42.6%. In another study, Muacevic et al. [20] 
treated 40 patients with 64 bone metastases with stereotactic 
body radiation therapy (SBRT). The number of metastatic 
lesions was less than 2 and the lesions were limited to the 
spine. The mean follow-up time was 14 months and the 
estimated local control rate was 95.5% at 6, 12, and 24 months. 
Some minor adverse effects were reported, including mild 
nausea in 5 men (12.5%) and a silent rib fracture in 1 patient 
(2.5%). Ahmed et al. [21] treated one liver lesion and one LN 
lesion in addition to 19 bone metastases. They observed a 
100% local control rate at 4.8 months and that 9 patients 
(53%) reached an undetectable serum PSA. Six of  the 11 
patients (55%) with hormone refractory disease achieved 
either undetectable or declining PSA at the time of analysis. 
A retrospective multicenter analysis also showed similar 
results. Ost et al. [22] treated 119 patients with 163 metastatic 
lesions including LN, bone, and viscera were treated with 
SBRT. With a median follow-up of 5 years, overall survival 
(OS) was 88% and distant progression-free survival was 
21 months (95% confidence interval [CI], 15–27). The 3- and 
5-year distant progression-free survival rates were 31% and 
15%, respectively, and the 3- and 5-year local progression-free 
survival rates were 93% and 92%, respectively. 
The studies above allowed ADT before patients received 
RT because of metastatic or recurrent prostate cancer. Some 
studies investigated whether repeated SBRT could postpone 
the initiation of palliative ADT in patients with limited 
metastatic lesions. Berkovic et al. [23] studied 24 patients 
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with up to 3 metastatic lesions following biochemical 
recurrence after local curative treatment. None of  the 
patients had been treated with ADT before they received 
RT. The authors defined ADT-free survival (ADT-FS) as 
the time interval between the first day of SBRT and the 
initiation of ADT. With a median follow-up of 24 months, 10 
patients started with ADT resulting in a median ADT-FS of 
38 months. In another study, Decaestecker et al. [24] treated 
50 patients with 70 metastatic lesions and observed a local 
control rate of 100% at 2 years. The median progression-free 
survival was 19 months (95% CI, 13–25) and median ADT-
FS was 25 months (95% CI, 20–30). On univariate analysis, 
the authors found that a short PSA doubling time was 
a significant predictor for both progression-free survival 
(hazard ratio [HR], 0.90; 95% CI, 0.82–0.99) and ADT-FS (HR, 
0.83; 95% CI, 0.71–0.97). 
The studies mentioned above concerned the management 
of  metachronous metastatic lesions of  prostate cancer. 
Schick et al. [25] studied 50 prostate cancer patients who 
were diagnosed with not only metachronous metastasis but 
also synchronous metastasis. With a median follow-up of 
31 months, 4-year biochemical relapse-free survival (bRFS), 
clinical failure-free survival, and OS rates were 54.5%, 
58.6%, and 92%, respectively. The number of metastases and 
number of radiation doses were related to improved bRFS. 
As reviewed, metastasis-directed stereotactic RT is 
deemed safe and suitable for managing recurrent prostate 
cancer because it has an acceptable local control rate and 
relatively low rate of  toxicity. However, to evaluate the 
benefit on oncologic outcomes, more precise randomized 
controlled trials (RCTs) are needed. Another advantage 
of  SBRT on metastatic lesions is that it seems to delay 
ADT initiation in patients with recurrent prostate cancer. 
Long-term ADT induces several significant physical and 
psychological adverse effects, because of the castration level 
of testosterone. These side effects include an increased risk 
of  cardiovascular disease, sexual impairment, metabolic 
syndrome, loss of  lean body mass, osteoporosis, fracture, 
cognitive impairment, fatigue, and anemia. Furthermore, 
in some patients, ADT may decrease overall life expectancy 
[26-30]. In this aspect, deferring the start of ADT may help 
patients live with a better quality of life. 
3. Prostatectomy in oligometastatic prostate cancer
Gandaglia et al. [31] assessed perioperative and long-
term oncologic outcomes of RP in oligometastatic prostate 
cancer. Eleven patients who had 5 or fewer metastatic 
lesions were treated with RP and extended pelvic LN 
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7-year clinical progression- and cancer-specific mortality-free 
survival rates were 45% and 82%, respectively. Heidenreich 
et al. [32] reported a case-control study examining the role 
of  cytoreductive radical prostatectomy (CRP) in selected 
men with limited metastatic disease. A total of 23 patients 
diagnosed with prostate cancer with less than three osseous 
metastases, absence of visceral or extensive LN metastasis, 
and PSA decrease to <1.0 ng/mL after ADT were included 
and underwent CRP. The control group consisted of  38 
patients with metastatic prostate cancer who received only 
ADT. Median time to castration-resistant prostate cancer 
was delayed in the CRP group compared with the control 
group (40 months vs. 29 months, p=0.04). The CRP group 
also experienced significantly better clinical progression-free 
survival (38.6 months vs. 26.5 months, p=0.032) and cancer-
specific survival (CSS) (95.6% vs. 84.2%, p=0.043). They also 
reported complications and functional outcome. Among 
38 patients, 3 patients underwent interventions such as 
percutaneous drainage or laparoscopic marsupialization due 
to lymphocele and 3 patients experienced DVT. A total of 21 
patients were continent, but 2 patients needed two to four 
pads per day.
These 2 studies are all of the available research on RP in 
oligometastatic prostate cancer. Thus, it is hard to evaluate 
the benefit of local therapy with so few studies. Because an 
important issue in oligometastasis is the possibility of curing 
advanced disease with local therapy, it is necessary to try to 
estimate the effectiveness of local therapy by using review 
studies that report the benefit of local therapy on advanced 
or metastatic prostate cancer.
TREATMENT OF LOCALLY ADVANCED 
OR METASTATIC PROSTATE CANCER
1. Locally advanced or LN-positive prostate cancer
Various combination therapies have been offered to 
treat locally advanced prostate cancer. Historically, the role 
of external irradiation in patients with locally advanced 
disease was controversial because of poor oncologic outcomes 
as the result of undetectable micrometastasis. Therefore, the 
combination of RT and ADT was offered. Bolla et al. [33] 
reported the results of a randomized phase 3 trial assessing 
the benefit of the addition of ADT to external irradiation 
in patients with prostate cancer with high metastatic risk. 
With a median follow-up of 9.1 years, the 10-year OS rate 
was 39.8% (95% CI, 31.9–47.5) in patients receiving RT alone 
and 58.1% (95% CI, 49.2–66.0) in those receiving combined 
treatment (HR, 0.60; 95% CI, 0.45–0.80; p=0.0004). The 10-year 
clinical disease-free survival was 22.7% (95% CI, 16.3–29.7) 
in the RT-alone group and 47.7% (95% CI, 39.0–56.0) in the 
combined treatment group (HR, 0.42; 95% CI, 0.33–0.55; 
p<0.0001). Another randomized study showed similar results. 
At 10 years, the absolute survival rate was greater in the 
adjuvant ADT group than in the control group (49% vs. 39%, 
p=0.002) [34]. 
The results of  a population-based study showed that 
about 33% of  patients who underwent RP experienced 
positive surgical margins [35]. Another study reported that 
among patients who underwent RP, 9% had seminal vesicle 
invasion [36]. These unfavorable pathologic results are 
associated with a higher rate of local failure. To improve 
local control in patients with undesirable pathologic results, 
adjuvant RT has been suggested. One RCT reported that 
metastasis-free survival as well as OS was significantly 
greater in the RP with adjuvant RT group than in the 
control group. Another RCT reported that progression-free 
survival was superior in an RP with adjuvant RT group 
than in a non-RT group, but that OS and metastasis-free 
survival were similar between groups [37,38]. 
As for locally advanced prostate cancer, multimodal 
therapy has also been examined for LN-positive disease. 
One matched analysis assessed the impact of combination 
adjuvant hormonal therapy (HT) and RT on the survival of 
patients with prostate cancer and pathologically confirmed 
LN metastasis. Patients treated with adjuvant RT with HT 
had significantly higher CSS and OS rates than did patients 
treated with HT alone at 5, 8, and 10 years after surgery 
(95%, 91%, and 86% vs. 88%, 78%, and 70%, and 90%, 84%, and 
74% vs. 82%, 65%, and 55%, respectively; p=0.004 and p<0.001, 
respectively) [39]. 
When we look at studies focused on the advantage of 
definitive local therapy of prostate for local disease control, 
the Scandinavian Prostate Cancer Group Study 7 and 
the Swedish Association for Urological Oncology 3 trial 
reported that cancer-specific mortality (11.9% vs. 23.9%) and 
overall mortality (29.6% vs. 39.4%) were lower in the RT 
with ADT group than in the ADT alone group in locally 
advanced prostate cancer [40]. Warde et al. [41] performed 
another randomized phase 3 trial involving 1,205 patients 
who were randomly assigned (602 in the ADT-only group 
and 603 in the ADT and RT group). With a median follow-
up of 6 years, they found that the addition of RT to ADT 
improved OS at 7 years (74% vs. 66%; HR, 0.77; p=0.033) 
compared with ADT alone in locally advanced prostate 
cancer. Another randomized phase 3 trial showed a similar 
result. Mottet et al. [42] reported that combined therapy was 
related with higher 5-year progression-free survival (60.9% 
vs. 8.5%), lower loco-regional progression (9.8% vs. 29.2%), and 
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lower metastatic progression (3.0% vs. 10.8%) compared with 
ADT alone. Referring to the RCTs above, it appears that 
RT for local control may help to reduce the risk of disease 
progression and improve loco-regional control when it is 
combined with ADT.
Some retrospective studies are available to evaluate 
the effectiveness of  local therapy of  the primary tumor 
for patients with LN-positive prostate cancer. Lin et al. [43] 
assessed the effect of the addition of RT to ADT on survival 
with clinically node-positive prostate cancer using the 
National Cancer Data Base. Of 3,540 patients, 1,141 patients 
(32.2%) were treated with ADT alone and 1,818 (51.4%) 
received ADT with RT. Compared with ADT alone, the 
addition of ADT to RT was associated with a 50% decreased 
risk of 5-year overall mortality. Engel et al. [44] reported the 
effectiveness of RP in LN-positive prostate cancer. In that 
study, a total of 938 LN-positive patients from the Munich 
Cancer Registry were studied: 688 patients had received RP 
and 250 patients had not. With 5.6 years of median follow-
up, 10-year OS and 10-year estimated CSS were 64% and 86% 
with RP and 28% and 40% with aborted RP, respectively. 
Another study based on the Surveillance, Epidemiology, 
and End Results (SEER) database showed similar results. 
Rusthoven et al. [45] divided 3,787 patients into clinical (cN+) 
and pathologically confirmed (pN+) LN-positive cohorts. 
Among cN+ patients, 340 patients underwent external beam 
radiation therapy (EBRT) and 456 had no local therapy. 
Outcomes for cN+ patients demonstrated that the EBRT 
group had a greater 10-year OS rate (45% vs. 29%, p<0.001) 
and CSS rate (67% vs. 53%, p<0.001) than did the no local 
therapy group. Among 2,991 pN+ patients, 2,334 patients 
underwent local therapy (RP, 1,709; EBRT, 293; both, 332) 
and 657 patients had no local therapy. Outcomes for pN+ 
showed favorable results in the local therapy group, with 
10-year OS rates of 65% vs. 42% (p<0.001) and CSS rates of 
78% vs. 56% (p<0.001). Among pN+ patients, there was no 
significant difference in survival between RP versus EBRT 
and RP with or without adjuvant EBRT.
2. Metastatic prostate cancer
The early studies related to local therapy in metastatic 
prostate cancer evaluated RP or RT as a factor influencing 
ADT for recurrent prostate cancer. Swanson et al. [46] 
followed until death 94 patients in whom primary RT failed 
and 67 in whom RP failed. All patients received ADT. This 
study showed that more patients in the RT group (78%) 
died of prostate cancer than in the RP group (63%, p=0.04). 
Thompson et al. [47] used data from the Southwest Oncology 
Group Study 8894, which was a randomized double-
blind prospective phase III trial comparing orchiectomy 
plus the antiandrogen flutamide with orchiectomy plus 
placebo in men with metastatic prostate cancer [48]. The 
authors evaluated the impact of RP and RT on outcomes 
in patients with metastatic prostate cancer. They reported 
that previous RP in patients with metastatic prostate cancer 
was associated with a decreased risk of death (HR, 0.77; 95% 
CI, 0.53–0.89) relative to those who had not received RP. 
However, previous RT was associated with a greater risk 
of death in those who had previously undergone RP and in 
those who received no definitive earlier therapy. 
Table 2 shows the studies related to local therapy of 
the prostate in metastatic prostate cancer. First, Culp et 
al. [49] used data from the SEER database and showed 
that definitive treatment of prostate cancer was related to 
a survival benefit in patients diagnosed with metastatic 
prostate cancer. For a total of  8,185 patients, the 5-year 
OS rate and predicted disease-specific survival rate were 
higher in patients undergoing RP (67.4% and 75.8%) or 
brachytherapy (52.6% and 61.3%) than in patients who 
underwent no surgery or RT (22.5% and 48.7%, respectively; 
p<0.001). In the multivariable competing risk regression 
analysis, patients treated with RP had a 62% lower risk 
of  cancer-specific mortality (subhazard ratio [SHR], 0.38; 
95% CI, 0.27–0.53; p<0.001) and patients who underwent 
brachytherapy had a 32% lower risk (SHR, 0.68; 95% CI, 
0.49–0.93; p=0.018). Data from the Munich Cancer Registry 
showed a survival benefit of  RP in metastatic prostate 
cancer. In a study of 1,538 patients newly diagnosed with 
metastatic prostate cancer, the RP group showed a 5-year 
OS rate of 55% compared with 21% in the non-RP group 
(p<0.01) [50]. Antwi and Everson [51] used data from the 
SEER database and showed similar results. Interestingly, 
the authors used propensity score analysis in addition to the 
conventional multivariable survival model. In the propensity 
score analysis, those receiving RP or BT had a lower risk of 
all-cause death regardless of extent of metastasis (M1a, M1b, 
M1c). Adjusted HR associated with RP was 0.18 (95% CI, 
0.07–0.50; p=0.0008), 0.22 (95% CI, 0.16–0.30; p<0.0001), and 0.23 
(95% CI, 0.16–0.35; p<0.0001) relative to no local therapy for 
metastatic disease, respectively. 
Another population-based study also used the SEER 
database. Unlike the previous studies that used SEER, 
Satkunasivam et al. [52] divided the RT group into an 
intensity-modulated radiation therapy (IMRT) group and 
a conformal radiation therapy (CRT) group. They excluded 
patients with 15 or fewer treatment claims because such 
treatment likely represented palliative radiation. In addition, 
they also excluded patients who had received ADT by using 
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billing-derived patient comorbidity and underwent early (less 
than 6 months) bone radiation because such early treatment 
might be a marker of advanced disease. With propensity 
score analysis, they observed that RP and IMRT were 
related to a lower risk of cancer-specific mortality with HRs 
of 0.48 (95% CI, 0.27–0.85; p=0.01) and 0.38 (95% CI, 0.24–0.61; 
p<0.001), respectively. However, CRT was not associated with 
a survival benefit relative to no local therapy (HR, 0.85; 
95% CI, 0.64–1.14; p=0.3). Parikh et al. [53] showed consistent 
results in a study that used the National Cancer Database. 
They also reported that the use of RP and IMRT but not 
CRT to treat the primary disease was associated with 
improvements in OS for patients with metastatic prostate 
cancer.
Cho et al. [54] performed a case-control comparison 
evaluating the efficacy and toxicity of RT for the primary 
tumor in prostate cancer with metastasis. Among 140 men 
who were involved in the study, 38 patients underwent 
prostate RT, 39 patients underwent palliative RT, and the 
remaining 63 men did not receive any RT. They found that 
3-year OS (69% vs. 43%, p=0.004) and 3-year biochemical 
failure-free survival (52% vs. 16%, p=0.002) were improved 
in prostate RT patients relative to the group who did not 
receive any RT. In the multivariate analysis, prostate RT 
was a significant predictor of OS (HR, 0.43; p=0.015). There 
was no grade 3 or greater toxicity among the patients who 
received prostate RT. 
RATIONALE FOR LOCAL TREATMENT IN 
METASTATIC PROSTATE CANCER
Although most studies that have evaluated the benefit 
of  local therapy on LN-positive and metastatic prostate 
cancer have been retrospective, the results suggest that local 
therapy may improve survival. However, the mechanism 
of the survival benefit of  local therapy or cytoreductive 
surgery in metastatic prostate cancer is unclear. The “seeding 
and soil” theory is an important and widely accepted theory 
in cancer biology. It explains metastasis as being determined 
by interactions between the “seed” and the “soil.” The “seed” 
has been renamed the progenitor cell, initiating cell, cancer 
stem cell, or metastatic cell, and the “soil” as host factors, 
stroma, or the organ microenvironment [55]. Haffner et al. [56] 
traced the evolution of a lethal cell clone from the primary 
cancer to metastasis through samples collected during 
disease progression and at the time of death. The authors 
used whole-genome sequencing and molecular pathological 
analyses to characterize the lethal cell clone. They found 
that the lethal clone arose from a small, relatively low-
grade cancer focus in the primary tumor and not from the 
bulk, higher-grade primary cancer or from a LN metastasis 
resected during RP. Lindberg et al. [57] tried to identify 
the area in the prostate that gave rise to metastasis by 
searching for metastatic-specific DNA alterations in multiple 
regions of  the prostate. They found that the clone most 
closely related to the metastasis was found in an intraductal 
carcinoma of the prostate. Traditionally, it has been thought 
that seeding of  tumor cells is a unidirectional process. 
However, Kim et al. [58] showed that circulating tumor cells 
can also colonize their tumors of origin in a process they 
called ‘‘tumor self-seeding.’’ Thus, the primary tumor can act 
as a self-seeding site for circulating tumor cells primed and 
deposited from established metastatic sites. Local therapy of 
the primary tumor or a metastatic site may alter the tumor 
biology and result in depressed growth or may limit the 
establishment of new metastatic sites.
Some preclinical studies support the role of cytoreductive 
surgery. Predina et al. [59] injected TC1 or LKR tumor 
cells into mice for induction of metastatic lung cancer and 
then performed cytoreductive surgery. They found that 
cytoreductive surgery helps to restore anti-tumor potency 
in immunotherapy for advanced cancer. The immune 
mechanisms that explained this restoration of anti-tumor 
immune responses included increased CD8 T-cell trafficking 
and reduced myeloid-derived suppressor cell populations. 
We have also reviewed many retrospective studies on 
local therapy of the prostate in metastatic prostate cancer 
in the clinical setting. Most studies showed a consistent 
survival benefit of local therapy compared with nonlocal 
therapy. Retrospective studies have some limitations, 
however, such as treatment selection bias and the effect 
of unmeasured factors. Therefore, prospective randomized 
controlled studies are needed. There are currently many 
ongoing prospective randomized trials evaluating the role 
of primary tumor treatment in metastatic prostate cancer. 
Many of these are limited to oligometastatic prostate cancer. 
With data from these trials, we could understand the role 
of local therapy of the prostate and change the treatment 
paradigm of metastatic prostate cancer. 
CONCLUSIONS
Oligometastasis is a metastatic status with limited 
metastatic lesions. It is thought of as an intermediate status 
between localized disease and widely metastatic disease, 
and it is possible to treat this stage with a curative aim 
in selected patients. However, no consensus exists on the 
definition of  oligometastasis in prostate cancer. Thus, a 
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definition of oligometastasis is needed that is based not only 
on the number of metastatic lesions but also on the sites 
of metastasis, because the affected sites are also related to 
survival in metastatic disease. Stereotactic RT of metastatic 
lesions in limited recurrent prostate cancer is a suitable and 
safe modality for managing oligometastatic prostate cancer; 
it has a good local control rate and a low rate of  severe 
toxicity. In addition, stereotactic RT can help to improve 
the quality of  life by delaying the initiation of  ADT. 
Although only a few retrospective studies are available, the 
data suggest that patients with metastatic prostate cancer 
undergoing local therapy might have superior survival 
compared with patients not undergoing local therapy. There 
are many ongoing prospective RCTs related to local therapy 
in oligometastatic prostate cancer. These ongoing studies 
will help us to better understand the role of local therapy in 
oligometastatic prostate cancer. 
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